ArticleFrontiers in pharmacology2026
The mechanism of Vicenin-2 in ameliorating skin photoaging: involvement of m6A-modified macrophage polarization.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skin photoaging is primarily induced by ultraviolet radiation and is closely associated with chronic inflammation and degradation of the extracellular matrix, with an imbalance in macrophage polarization (elevated M1/M2 ratio) being a key factor. Methods: This study first conducted single-cell sequencing analysis to investigate the correlation between macrophage subtypes and photoaging. At the same time, we investigated the effects and mechanisms of the natural flavonoid Vicenin-2 on photoaging through both Results: It was found that in the photodamage model, the infiltration of pro-inflammatory M1 macrophages significantly increased, and the key regulatory factor KIAA1429 was positively correlated with the level of anti-inflammatory M2 macrophages. The results showed that Vicenin-2 significantly alleviated skin damage, improved hydration and collagen organization, and promoted the shift of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Mechanistically, Vicenin-2 upregulated the m6A modification regulator KIAA1429, enhanced overall m6A RNA methylation, and inhibited NF-κB pathway activation by suppressing p65 phosphorylation. Conclusion: The findings indicate that Vicenin-2 may mitigate skin photoaging by modulating macrophage polarization toward the M2 phenotype through m6A-dependent regulation of the NF-κB signaling pathway, supporting its potential as a novel topical agent for photoaging intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.